Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Gastric 300: Avelumab vs Chemotherapy in 3rd-line Gastric Cancer
NCT02625623Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Dec 2015
- Primary completion
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of avelumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by EMD Serono. Started Dec 2015; status: completed.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02625623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625623.